umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The critical interplay between bone resorbing and bone forming cells
Umeå University, Faculty of Medicine, Department of Odontology. Centre for Bone and Arthritis Research at Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID iD: 0000-0002-3579-1960
Umeå University, Faculty of Medicine, Department of Odontology.
Umeå University, Faculty of Medicine, Department of Odontology.ORCID iD: 0000-0002-8244-5200
2019 (English)In: Journal of Clinical Periodontology, ISSN 0303-6979, E-ISSN 1600-051X, Vol. 46, p. 33-51Article in journal (Refereed) Published
Abstract [en]

Aim: In this article, the interplay between bone resorbing and bone forming cells is reviewed.

Method: This review examines the comprehensive literature on the interaction between bone resorption and bone formation.

Results: Coupling between bone resorption and bone formation refers to the process within basic multicellular units, in which osteoclastic bone resorption is met by the differentiation of osteoblasts and their bone forming activity. There are many possible signalling molecules that contribute to coupling at the asynchronously working remodelling sites throughout our skeleton. These include growth factors released from the bone matrix during bone resorption, soluble and membrane products of the osteoclasts and their precursors and signals from osteocytes.

Conclusions: In this review, we describe the potential roles of a number of these factors, whose interactions are essential for a tight control of coupling within individual remodelling units, in order to control skeletal mass. Both pre‐clinical evidence and clinical evidence pinpoint that molecules in the WNT signalling pathway could be promising bone augmentation therapeutic targets. Regarding oral implications, there is support, from preclinical studies in rats, that anti‐sclerostin antibodies can restore alveolar bone mass.

Place, publisher, year, edition, pages
John Wiley & Sons, 2019. Vol. 46, p. 33-51
National Category
Dentistry Orthopaedics
Identifiers
URN: urn:nbn:se:umu:diva-161525DOI: 10.1111/jcpe.13051ISI: 000472200500003PubMedID: 30623989OAI: oai:DiVA.org:umu-161525DiVA, id: diva2:1337039
Funder
Swedish Research CouncilVästerbotten County CouncilSwedish Rheumatism AssociationAvailable from: 2019-07-11 Created: 2019-07-11 Last updated: 2019-07-11Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Lerner, Ulf H.Kindstedt, ElinLundberg, Pernilla

Search in DiVA

By author/editor
Lerner, Ulf H.Kindstedt, ElinLundberg, Pernilla
By organisation
Department of Odontology
In the same journal
Journal of Clinical Periodontology
DentistryOrthopaedics

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 4 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf